Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

MEDICAL TECHNOLOGY ASSESSMENT COUNCIL PROPOSAL CLEARS CONGRESS, as the House and Senate wrapped up business before their Oct. 12 adjournment. The provision, which would establish a Council on Health Care Technology within the Natl. Academy of Sciences, awaits the President's signature as part of a larger bill, S 771, which would set up 13 health promotion research centers by FY 1988. The provision -- a compromise between Senate and House measures S 2559 and HR 5496, respectively -- also calls for the renaming of the Natl. Center for Health Services Research to the Natl. Center for Health Services Research and Health Care Technology Assessment. Of the funding authorized under the bill for the new center, $3 mil. in FY 1985, $3.5 mil. in FY 1986, and $4 mil. in FY 1987 would be earmarked for health care technology assessment activities. In an Oct. 10 release, Health Industry Mfrs. Assn. President Frank Samuel said the new legislation would "strengthen the ability of the Natl. Center for Health Services Research (NCHSR) to respond to Medicare coverage issues." He also said the bill recognized the impact of Medicare coverage on new technology development by forming an advisory council with private sector representation and by providing supportive funding.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts